Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

Blood

Volumn 99, Issue 1, 2002, Pages 319-325

  Graham, Susan M ^a   Jørgensen, Heather G ^a   Allan, Elaine ^a   Pearson, Charlie ^a   Alcorn, Michael J ^a   Richmond, Linda ^a   Holyoake, Tessa L ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; BONE MARROW CELL; CELL DIVISION; CELL VIABILITY; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; FLUORESCENCE ACTIVATED CELL SORTING; GENE OVEREXPRESSION; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; STEM CELL;

EID: 0036090222     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.1.319     Document Type: Article

References (38)

1. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining
2. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia
3. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene
4. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210 bcr-abl protein
5. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia
6. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3
7. Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia
8. + chronic myelogenous leukemia and effects of intensive treatment
9. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class
10. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
11. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
12. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
13. In vivo eradication of human BCR/ABL-positive cells with an ABL kinase inhibitor
14. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
15. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
16. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
17. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
18. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
19. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
20. BCR/ABL gene amplification: A possible mechanism of drug resistance in patients treated with an ABL-specific kinase inhibitor
21. Relapse in Ph+ leukemia patients treated with an ABL-specific kinase inhibitor is associated with reactivation of bcr-abl
22. - cell production in vitro
23. + cells from patients with chronic myeloid leukemia
24. + subpopulations of human bone marrow cells
25. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukaemia
26. BCR-ABL accelerates C2-ceramide-induced apoptosis
27. + cells from patients with chronic myeloid leukemia
28. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia
29. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents
30. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
31. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-kinase/AKT pathway
32. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL-expressing cells, demonstrating synergy between AG490 and STI571
33. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farne-syl transferase inhibitor SCH66336
34. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia
35. Evolution of bone marrow transplantation-the original immunotherapy
36. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells
37. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells
38. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents